The top 15 biopharma licensing deals of 2020 Biogen, under increasing public pressure, to offer early access to experimental ALS med Lilly scraps IL-23 psoriasis program despite phase 3 success, focuses on IBD race against AbbVie, J&J Sponsored: Look before you leap: How a joined-up development strategy pays off for early-stage biotechs Pyxis debuts next-gen cancer ADCs from under Pfizer's wing Ex-Lilly R&D lead Bilenker launches new cancer biotech with Novartis' oncology R&D head Engelman Sanofi to divest Pennsylvania R&D site, cut 75 employees Astellas takes $540M impairment charge over Audentes' gene therapy trial hold GV hires industry veteran Lynch to coach biotech CEOs, identify new investments Verily, LivaNova kick off study of nerve stimulation for treatment-resistant depression Insights into how COVID outsmarts the gut's immune response could point to new treatments Featured Story | By Phil Taylor Oncology, specifically immuno-oncology, was the dominant theme in biopharma licensing last year, as cancer drugs accounted for half of the top deals. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus After months of holding its ground on not offering an experimental ALS drug to patients outside of clinical trials, Biogen is laying out a plan to do just that. In the two-part program, Biogen will begin with patients with a genetic form of ALS whose diseases is worsening the fastest in mid-July, before expanding into the broader population of patients with this type of ALS. read more By Nick Paul Taylor Eli Lilly has scrapped plans to seek approval for mirikizumab in psoriasis. Lilly chose not to enter the crowded market despite the anti-IL-23p19 antibody outperforming Novartis' Cosentyx in a phase 3 trial last year. read more Sponsored By: Parexel Biotech A well-thought-out strategic development plan that brings together nonclinical, clinical, regulatory and commercial experts can improve efficiencies, cut costs, shorten timelines, and increase the chances of success for a new drug program. read more By Annalee Armstrong Cambridge, Massachusetts-based Pyxis is developing three antibody-drug conjugates called PYX-201, PYX-202 and PYX-203 for difficult-to-treat cancers. Each therapy could be effective against a number of malignancies with similar traits. read more By Ben Adams Josh Bilenker, M.D., and Jeff Engelman M.D., Ph.D., have joined forces to create a new cancer biotech, tapping their combined considerable experience to find new solutions to old oncology research problems. read more By Annalee Armstrong Sanofi will divest an R&D facility in Malvern, Pennsylvania, where investigational medical products are packaged and distributed as the French pharmaceutical giant undergoes a strategic transformation. read more By Ben Adams Astellas paid $3 billion to snap up biotech Audentes in 2019 but is still paying for the biotech more than a year down the line. read more By Nick Paul Taylor GV has hired serial biotech chairman Dan Lynch as its first executive venture partner. The appointment positions Lynch to serve as a coach and adviser to executives at GV’s portfolio companies. read more By Andrea Park The Uncover study will collect a range of daily mental and physical health data from patients who are using vagus nerve stimulation therapy to relieve the symptoms of major depressive disorder. read more By Arlene Weintraub European researchers used 3D tissue models, or organoids, of the human gut to determine that a particular subpopulation of cells is most affected by SARS-CoV-2. The enhanced understanding of those cells mount an immune response to the virus could enhance the search for new COVID-19 therapies, they said. read more Resources Sponsored by: Datacubed Health The average clinical trial spends $40,000 per patient. Yet despite these high costs, most trials struggle to retain patients. Sponsored By: AmerisourceBergen Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored by: PulsePoint Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Medical Affairs Strategic Summit (MASS) Virtual May 5-7, 2021 | Virtual Event TMF Virtual Summit May 18-20, 2021 | Virtual Event Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Biopharma Supply Chain June 29-30, 2021 | Virtual Event | 